Ad-hoc Releases

select year
Date Headline PDF
June 24, 2022 Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001

Corporate News

select year
Date Headline PDF
June 20, 2022 Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 and Variants of Concern
June 10, 2022 Kinarus Therapeutics Announces Name Change and Commences Trading on the SIX Swiss Exchange under ticker “KNRS”
June 3, 2022 Perfect Holding Completes Reverse Takeover Transaction with Kinarus
April 26, 2022 Kinarus Receives Grant of Key U.S. Patent for its Lead Therapeutic Candidate
April 20, 2022 Kinarus Shareholders Approve Reverse Takeover by Perfect Holding SA
April 12, 2022 Kinarus Receives Positive Recommendation from DSMB to Continue Phase 2 Trial in COVID-19
March 30, 2022 Kinarus Announces Signing of a Transaction Agreement with Perfect Holding
Date Headline PDF
December 13, 2021 Kinarus receives 7 Million CHF Grant from the Swiss Federal Funding Programme for COVID-19 Medicines
September 9, 2021 Kinarus Secures CHF 57 Million Capital Commitment
August 23, 2021 Preclinical Data Confirm Triple Mechanism of Action of Lead Compound KIN001 in COVID-19
August 17, 2021 Signature of a Memorandum of Understanding with Perfect Holding SA
April 26, 2021 Kinarus further strengthens its leadership with two reputed industry experts N/A
April 13, 2021 First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study
April 13, 2021 Kinarus AG: First Hospitalized COVID-19 Patient Dosed with KIN001 in Phase 2 Study N/A
January 21, 2021 Kinarus appoints Thierry Fumeaux, MD, as Chief Medical Officer